Highlights • Effective treatment options for recurrent endometrial carcinomas are limited.• Immune checkpoint inhibitor is a recent progress in cancer immunotherapy.• Reports on recurrent endometrial carcinomas managed by pembrolizumab are… Click to show full abstract
Highlights • Effective treatment options for recurrent endometrial carcinomas are limited.• Immune checkpoint inhibitor is a recent progress in cancer immunotherapy.• Reports on recurrent endometrial carcinomas managed by pembrolizumab are limited.
               
Click one of the above tabs to view related content.